duce the likelihood of litigious arguments concerning who knew what and when. 5 Individual manufacturers should not be in the position of determining what information is considered material for public dissemination.
No takes yet. Share an insight, caveat, or question.
Sherman et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: